JY
ADCT icon

Jeff Yass’s ADC Therapeutics ADCT Stock Holding History

Jeff Yass’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-18,200
Closed -$68.3K – 13295
2026
Q1 		$68.3K Sell
18,200
-6,200
-25% -$24.4K ﹤0.01% 12526
2025
Q4 		$86.1K Sell
24,400
-15,400
-39% -$62.5K ﹤0.01% 11535
2025
Q3 		$159K Buy
39,800
+24,100
+154% +$76K ﹤0.01% 11230
2025
Q2 		$42.1K Buy
+15,700
New +$33K ﹤0.01% 12160
2025
Q1 		– Sell
-19,000
Closed -$37.8K – 12377
2024
Q4 		$37.8K Sell
19,000
-54,700
-74% -$143K ﹤0.01% 11782
2024
Q3 		$232K Sell
73,700
-98,600
-57% -$311K ﹤0.01% 10158
2024
Q2 		$544K Buy
172,300
+43,900
+34% +$174K ﹤0.01% 8060
2024
Q1 		$577K Buy
+128,400
New +$474K ﹤0.01% 8165
2022
Q2 		– Sell
-11,500
Closed -$169K – 12775
2022
Q1 		$169K Sell
11,500
-65,300
-85% -$1.04M ﹤0.01% 11439
2021
Q4 		$1.55M Buy
76,800
+39,500
+106% +$952K ﹤0.01% 6133
2021
Q3 		$1.01M Buy
37,300
+21,600
+138% +$553K ﹤0.01% 7527
2021
Q2 		$382K Buy
15,700
+1,400
+10% +$32.5K ﹤0.01% 10241
2021
Q1 		$349K Buy
+14,300
New +$414K ﹤0.01% 10297

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jeff Yass's ADCT Position: Q2 2026 in Review

Jeff Yass sold out of ADC Therapeutics (ADCT) in Q2 2026, closing a stake of 76,268 shares — an estimated $286K sold.

Jeff Yass first reported a position in ADCT in Q4 2020 and held it in 15 quarters. The position peaked at $2.42M in Q1 2021. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Jeff Yass reported no remaining ADC Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 76,268 ADC Therapeutics shares in Q2 2026, an estimated $286K.
  • Jeff Yass first reported a position in ADC Therapeutics in Q4 2020 and held it in 15 quarters.
  • Jeff Yass's ADC Therapeutics position peaked at $2.42M in Q1 2021.
  • 113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.